SureScreen Life Sciences Limited has been awarded a prestigious Technology Support Board grant of £140,000 to help bring the world’s first rapid genetic cancer analyser to market.

Using tumour cell material, SureScreen will use its research laboratory at Morley Retreat to analyse the specimens using traditional methods and compare them with results from the Q-Cancer project, which uses lab-on-a-chip technology to produce a result in less than 20 minutes. The Q-Cancer instrument will have a dramatic impact on the rapid and accurate diagnosis and staging of cancer.

Q-Cancer has the potential to ease the suffering and prolong the lives of the 12.7m new annually diagnosed cancer sufferers, globally, by enabling surgeons to immediately remove most, if not all of the tumour and oncologists to prescribe the correct treatment regime according to the type of cancer developed.